NICE Final Appraisal Favors Cost-Effectiveness Of Aromatase Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K's National Institute for Health & Clinical Excellence released a final appraisal determination Aug. 11 supporting the clinical benefit of aromatase inhibitors over tamoxifen in primary adjuvant and unplanned switch treatment of early-stage breast cancer